Orion Corporation

Paavo Huhtala

Arja Karjalainen

Arto J Karjalainen

Jari Ratilainen

Raimo E Virtanen

Olli Törmäkangas

Maire Eloranta

Juha-Matti Savola

Antti Haapalinna

Siegfried Wurster

Jyrki Lehtim&auml;ki

Victor Cockcroft

Maarit Hillil&auml;

Raimo Saxlund

Gerd Wohlfahrt

Anu Moilanen

Pekka Kallio

A compound of formula (I), an isomer, metabolite, or a pharmaceutically acceptable salt or ester thereof is disclosed. Compounds of the invention possess utility as a tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g. in the treatment or prevention of hypogonadism, muscle wasting, osteoporosis, benign prostate hyperplasia, obesity associated with a metabolic syndrome, male and female sexual dysfunction and reduced libido, and androgen decline in aging male or female.

Selective androgen receptor modulators

Compounds of formula (I) wherein R1 to R4, X and A are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g., in the treatment or prevention of male hypogonadism and age-related conditions such as andropause.

Propionamide derivatives useful as androgen receptor modulators

Imidazole derivatives having affinity for &agr;2 receptors

Imidazole derivatives

Polycyclic indanylimidazoles with alpha2 adrenergic activity

Imidazole derivatives having affinity for alpha2 receptors

Growing community of inventors

Espoo, Finland

Paavo Huhtala